0000899243-22-030480.txt : 20220906 0000899243-22-030480.hdr.sgml : 20220906 20220906190039 ACCESSION NUMBER: 0000899243-22-030480 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220901 FILED AS OF DATE: 20220906 DATE AS OF CHANGE: 20220906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Habibizad Nazila CENTRAL INDEX KEY: 0001913961 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 221229522 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-01 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001913961 Habibizad Nazila C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2022-08-31 5 A 0 E 414 25.37 A 9332 D Common Stock 2022-09-01 4 M 0 1670 A 11002 D Common Stock 2022-09-01 4 M 0 2208 A 13210 D Common Stock 2022-09-01 4 F 0 1342 68.15 D 11868 D Restricted Stock Units 2022-09-01 4 M 0 1670 0.00 D Common Stock 1670 8353 D Restricted Stock Units 2022-09-01 4 M 0 2208 0.00 D Common Stock 2208 15460 D Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,878 shares of Common Stock underlying the Reporting Person's RSUs. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Executive Vice President, Operations /s/ Miguel Carrillo, Attorney-in-Fact 2022-09-06